Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 1,231.2 million, a decrease of 4.1% compared to RMB 1,284.3 million for the same period in 2023[1] - Gross profit for the same period was RMB 396.3 million, down from RMB 484.0 million in 2023[1] - Profit attributable to owners of the company was RMB 85.0 million, compared to RMB 123.4 million in the prior year[1] - Operating profit for the six months was RMB 185.7 million, down from RMB 228.5 million in the same period last year[6] - Total comprehensive income for the period was RMB 87.7 million, down from RMB 129.9 million in the previous year[7] - The group reported a net profit of RMB 87,121,000 for the period, after tax expenses of RMB 38,027,000[19] - The company reported a net profit of RMB 126,219,000 for the same period, after tax expenses of RMB 53,718,000[21] - Net profit for the period was RMB 87.1 million, down from RMB 126.2 million in the same period of 2023[60] Dividends - The board declared an interim dividend of HKD 0.045 per share for the reporting period[1] - The company declared an interim dividend of HKD 0.045 per share, totaling HKD 71.6 million, to be paid on or around September 23, 2024[78] Assets and Liabilities - Total assets as of June 30, 2024, amounted to RMB 4,542.8 million, a decrease from RMB 4,637.8 million as of December 31, 2023[3] - Total liabilities decreased to RMB 3,356.2 million from RMB 3,523.7 million at the end of 2023[5] - As of June 30, 2024, total assets of the group amounted to RMB 4,542,815,000, while total liabilities were RMB 3,356,183,000[20] - The company’s current liabilities exceeded current assets by RMB 708,191,000 as of June 30, 2024[10] - The total trade payables as of June 30, 2024, were RMB 162,086 thousand, a slight decrease from RMB 164,351 thousand as of December 31, 2023[34] Cash Flow and Financing - The company reported a net cash position of RMB 587.1 million as of June 30, 2024, compared to RMB 811.2 million at the end of 2023[3] - The group’s operating cash flow is primarily supported by cash generated from operations, bank borrowings, and unused bank financing[10] - The company’s bank borrowings stood at RMB 813,500,000 as of June 30, 2024, compared to RMB 850,000,000 as of December 31, 2023[30] - The total bank and other borrowings as of June 30, 2024, were RMB 813.5 million, down from RMB 866.6 million as of December 31, 2023[67] - The group reported financing costs of RMB 60,966 thousand for the six months ended June 30, 2024, compared to RMB 49,039 thousand in 2023, reflecting an increase of 24%[39] Operational Highlights - The comprehensive hospital segment generated revenue of RMB 323,966,000 and a segment profit of RMB 72,356,000[19] - The health check center segment reported revenue of RMB 922,936,000 and a segment profit of RMB 215,616,000[19] - The revenue from the comprehensive hospital business was RMB 308.3 million, an increase of 2.1% from RMB 301.8 million in the same period of 2023[49] - The revenue from the health check business was RMB 922.9 million, a decrease of 6.1% from RMB 982.5 million in the same period of 2023[50] - The group added property, plant, and equipment, right-of-use assets, and intangible assets totaling RMB 321,778,000 during the period[20] Employee and Administrative Expenses - Employee benefit expenses for the first half of 2024 were RMB 501,699 thousand, an increase of 1.3% from RMB 496,103 thousand in the same period last year[38] - The group incurred administrative expenses of RMB 111,793,000 for the six months ended June 30, 2024[19] Market and Industry Insights - In 2023, the total number of medical visits in China reached 6.41 billion, a year-on-year increase of 9.4%[45] - The hospital industry saw 3.86 billion visits, with public hospitals accounting for 3.23 billion visits (up 6.7%) and private hospitals 640 million visits (up 9.3%) from the previous year[45] - The health check-up industry in China grew from 151.1 billion yuan in 2018 to 217 billion yuan in 2022, with a compound annual growth rate of approximately 9.46%[45] Corporate Governance - The company has not separated the roles of Chairman and CEO, with Dr. Fang Yixin holding both positions to facilitate the implementation of new business strategies[80] - The board consists of four executive directors and three independent non-executive directors, ensuring a strong element of independence[80] - The company has adopted the standard code of conduct for securities trading, confirming compliance by all directors during the reporting period[81] Auditor and Reporting - The external auditor, Hong Kong Lixin Dehao CPA Limited, conducted an independent review of the group's interim financial information during the reporting period[83] - The interim report will be published on the Hong Kong Stock Exchange and the company's website, containing all required information[83]

Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching HKD 1.2 billion for the fiscal year 2023[1]. - For the fiscal year ending December 31, 2023, the revenue from continuing operations was RMB 2,992.7 million, an increase of 26.0% compared to RMB 2,375.0 million for the fiscal year ending December 31, 2022[16]. - The gross profit for the fiscal year ending December 31, 2023, was RMB 1,249.5 million, reflecting a 34.8% increase from RMB 927.2 million for the fiscal year ending December 31, 2022[16]. - The profit attributable to owners of the company for the fiscal year ending December 31, 2023, was RMB 363.8 million, up 25.1% from RMB 290.8 million for the fiscal year ending December 31, 2022[16]. - The adjusted EBITDA for the fiscal year ending December 31, 2023, was RMB 1,072.4 million, representing a 30.9% increase from RMB 819.1 million for the fiscal year ending December 31, 2022[16]. - The company recorded a net profit of RMB 401.975 million for the fiscal year ending December 31, 2023, compared to RMB 267.2 million for the fiscal year ending December 31, 2022[17]. - Revenue from the health check business increased by 35.2% to RMB 2,386.0 million in 2023, compared to RMB 1,765.4 million in 2022[61]. - The average spending per customer rose by 2.6% to RMB 555.2 in 2023 from RMB 541.0 in 2022[55]. Market Expansion and Strategy - The company provided a positive outlook for 2024, projecting a revenue growth of 10% to 12%[1]. - New product launches included a telemedicine platform, which is expected to contribute an additional HKD 100 million in revenue in 2024[1]. - The company is expanding its market presence with plans to open 10 new clinics in tier-2 cities across China by the end of 2024[1]. - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[37]. - Future strategies include focusing on high-end health check services and expanding in key markets such as Shanghai, Beijing, Jiangsu, the Greater Bay Area, and Zhejiang[58]. User Engagement and Satisfaction - User data showed a growth in active patients by 20%, totaling 500,000 active patients by the end of 2023[1]. - The board announced a new strategy to improve patient engagement through digital health initiatives, aiming for a 30% increase in patient satisfaction scores[1]. - The company reported a significant increase in user data, with a year-over-year growth of 25% in active users[37]. - The company plans to enhance its digital platform, expecting a 50% increase in online engagement from users[37]. Research and Development - Research and development investments increased by 25%, focusing on advanced medical technologies and AI integration[1]. - The company has established partnerships with leading tech firms to leverage AI in healthcare, which is expected to drive innovation and efficiency[37]. - The company is investing in AI and 5G technology to adapt to current data demands in medical equipment[159]. Operational Efficiency - The company aims to enhance operational efficiency, targeting a 15% reduction in operational costs by 2025[1]. - The company has implemented measures to ensure that employees can confidentially report any concerns regarding financial reporting or internal controls[148]. - The company is focusing on optimizing its business expansion mechanisms and standardizing operational processes to mitigate risks associated with rapid growth[154]. Corporate Governance - The company is committed to high corporate governance standards and has complied with the corporate governance code throughout the reporting period[101]. - The board of directors consists of 4 executive directors (57.1%) and 3 independent non-executive directors (42.9%) as of December 31, 2023[111]. - The company has a policy ensuring that at least 10% of board members, senior management, and employees are female, with female employees making up approximately 81.5% of the total workforce[112]. - The company emphasizes compliance with legal and regulatory requirements in its governance practices[131]. Risk Management - The company has established a comprehensive risk management and internal control framework to actively manage risks associated with its strategic objectives[153]. - The company has strengthened its anti-fraud measures and established reporting channels to encourage employees to report any fraudulent activities[174]. - The company has established a crisis public relations management mechanism to prevent the escalation of risks and enhance public trust[169]. Sustainability and ESG Initiatives - The company has published ESG reports for eight consecutive years since 2016, reflecting a deepening understanding of ESG principles[200]. - An internal sustainable development system has been established to optimize ESG management processes[200]. - The integration of sustainable development concepts with business strategies aims to improve competitiveness and reduce operational risks[200]. Financial Management - The company maintains a cash flow management strategy to ensure sufficient liquidity for operational needs and has adequate unutilized borrowing capacity[96]. - The company is optimizing its capital management system to improve financial risk control and resource utilization efficiency, ensuring the safety and integrity of funds[166]. - The company has established a centralized fund management model to enhance the scientific management of financial resources and improve cash flow control[166].

Financial Performance - For the year ended December 31, 2023, the revenue from continuing operations was RMB 2,992.7 million, an increase of 26.0% compared to RMB 2,375.0 million for the year ended December 31, 2022[1]. - The gross profit from continuing operations for the year ended December 31, 2023, was RMB 1,249.5 million, reflecting a 34.8% increase from RMB 927.2 million for the year ended December 31, 2022[1]. - The profit attributable to owners of the company for the year ended December 31, 2023, was RMB 363.8 million, up 25.1% from RMB 290.8 million for the year ended December 31, 2022[1]. - The adjusted EBITDA from continuing operations for the year ended December 31, 2023, was RMB 1,072.4 million, representing a 30.9% increase from RMB 819.1 million for the year ended December 31, 2022[1]. - The operating profit for the year ended December 31, 2023, was RMB 656.9 million, compared to RMB 431.7 million for the year ended December 31, 2022[20]. - The net profit from continuing operations for the year ended December 31, 2023, was RMB 401.975 million, up from RMB 243.149 million for the year ended December 31, 2022[20]. - The company's net profit for the year ended December 31, 2023, was RMB 401,975 thousand, representing a 50.4% increase from RMB 267,187 thousand in 2022[25]. - Total comprehensive income for the year was RMB 402,350 thousand, up from RMB 268,912 thousand in the previous year, marking a growth of 49.5%[25]. Revenue Breakdown - Total revenue for the year ended December 31, 2023, was RMB 2,992,689,000, with a segment profit of RMB 868,925,000[60]. - The comprehensive hospital segment generated revenue of RMB 627,659,000, while the health check center segment contributed RMB 2,386,006,000[60]. - The health check-up business revenue reached RMB 2,386.0 million in 2023, a 35.2% increase from RMB 1,765.4 million in 2022, driven by a 31.8% growth in the number of check-ups and a 2.6% increase in average spending per person[137]. - Outpatient service revenue was RMB 84,198 thousand, down 4.3% from RMB 88,122 thousand in 2022[100]. - Inpatient service revenue increased to RMB 256,107 thousand, up 11.3% from RMB 230,269 thousand in 2022[100]. Assets and Liabilities - As of December 31, 2023, total assets amounted to RMB 4,637,755,000, with total liabilities of RMB 3,523,710,000[60]. - The company's equity attributable to owners increased to RMB 1,114,045 thousand from RMB 904,826 thousand, marking a growth of 23.1%[44]. - The total liabilities decreased to RMB 3,523,710 thousand from RMB 3,662,032 thousand, indicating a reduction of 3.8%[44]. - The financial liabilities of the group were RMB 3,269.1 million, a decrease from RMB 3,426.6 million as of December 31, 2022[8]. - Total assets as of December 31, 2023, amounted to RMB 4,637,755 thousand, a slight increase from RMB 4,566,858 thousand in 2022[34]. Employee and Operational Metrics - The number of employees in the group as of December 31, 2023, was 9,413, an increase from 8,737 as of December 31, 2022[16]. - The group operated 79 health check-up centers nationwide as of December 31, 2023, with 72 centers already in operation, covering 29 cities[158]. - The number of outpatient visits in the first nine months of 2023 reached 5.11 billion, a year-on-year increase of 6%[107]. - The nursing home operated at an occupancy rate of 89.6% as of December 31, 2023, down from 94.2% in 2022[110]. Cost and Expenses - The income tax expense for continuing operations in 2023 was RMB 143.7 million, compared to RMB 84.0 million in 2022, primarily due to the increase in profit from continuing operations[12]. - The group reported administrative expenses of RMB 223,845,000 and net impairment losses on financial assets of RMB 9,042,000[60]. - Employee benefit expenses increased to RMB 1,098,021, up from RMB 901,209 in 2022, reflecting a growth of approximately 21.8%[121]. - The sales cost for the health check business rose by 29.0% to RMB 1,260.5 million in 2023, driven by an increase in the number of health check visits[166]. Strategic Initiatives - The company established a Shanghai medical service center, enhancing its market expansion efforts by connecting with over 150 top doctors from 20 hospitals[129]. - The company’s collaboration with Fudan University hospitals focuses on oncology, indicating a strategic move towards specialized medical services[130]. - The group plans to continue focusing on high-end health check-up services and expand its presence in key markets such as Shanghai, Beijing, Jiangsu, the Greater Bay Area, and Zhejiang[158]. - The company implemented a "patient satisfaction first" action plan to enhance patient experience and satisfaction[163]. - The company aims to establish itself as one of the three major medical centers in Nantong by creating a comprehensive hospital with a focus on high-quality specialty development[163]. Dividends and Shareholder Returns - The group declared a special dividend of HKD 0.13 per share, totaling HKD 206,742,000 (approximately RMB 187,904,000)[153]. - Basic and diluted earnings per share attributable to owners of the company from continuing operations for the year ended December 31, 2023, was RMB 0.23, compared to RMB 0.18 for the year ended December 31, 2022[23]. - Basic and diluted earnings per share increased to RMB 0.23 from RMB 0.15, indicating a growth of 53.3%[31].

智通财经APP讯，瑞慈医疗(01526)发布公告，预期公司截至2023年12月31日止年度取得的公司拥有人应占溢利不超过人民币3.9亿元及不少于人民币3.5亿元。而截至2022年12月31日止年度的公司拥有人应占溢利为人民币2.91亿元。 公告称，预期取得截至2023年12月31日止年度的公司拥有人应占溢利主要由于2023年公司体检业务强劲复苏并实现进一步增长，全年收入大幅提升。 ...

Financial Performance - The company reported a revenue of HKD 500 million for the first half of 2023, representing a 15% increase compared to the same period last year[11]. - The company expects a revenue growth of 10-12% for the second half of 2023, driven by new service offerings and market expansion[11]. - The gross margin improved to 40%, up from 35% in the previous year, due to operational efficiencies[11]. - The health check business revenue grew by 101.2% in the first half of 2023, despite being a traditional off-peak season[29]. - The group's revenue from continuing operations reached RMB 1,284.3 million, a 59.6% increase from RMB 804.5 million in the same period of 2022, primarily due to the recovery of the health check business[36]. - Health check business revenue surged by 101.2% to RMB 982.5 million, driven by a 89.2% increase in customer numbers and a 6.4% rise in average spending per customer[39]. - The company reported a profit of RMB 126,219 thousand for the six months ended June 30, 2023, compared to a loss of RMB 168,553 thousand in the same period of 2022[142]. - The net profit for the six months ended June 30, 2023, was RMB 126.2 million, a significant improvement from a net loss of RMB 168.6 million in the same period of 2022[181]. - Adjusted EBITDA for the same period was RMB 431.1 million, with an adjusted EBITDA margin of 33.6%, compared to RMB 129.9 million and 16.1% in 2022[183]. Operational Developments - User data indicates a growth in active patients by 20%, reaching a total of 150,000 patients as of June 30, 2023[11]. - Investment in new technology development increased by 25%, focusing on telemedicine and AI-driven healthcare solutions[11]. - The company plans to expand its market presence in Tier 2 cities, targeting an additional 30% increase in service locations by the end of 2024[11]. - A strategic acquisition of a local healthcare provider is anticipated to enhance service capabilities and increase market share by 5%[11]. - The company has launched a new outpatient service, which is projected to contribute an additional HKD 50 million in revenue by the end of 2023[11]. - The company aims to implement a dual-brand strategy with "Ruici Health Check" and "Xingyuan International Health Check" to meet diverse consumer health management needs[29]. - The company plans to enhance service quality and operational efficiency while focusing on high-quality development and talent cultivation for sustainable growth[29]. - The hospital's second-phase comprehensive ward building, with 1,500 beds, was officially put into use in April 2023, significantly enhancing its medical service capacity[30]. Market Trends - The health check industry in China is projected to grow from RMB 468 billion in 2012 to RMB 1,890 billion in 2021, with a compound annual growth rate (CAGR) of 16.78%, and is expected to reach RMB 3,900 billion by 2025[14]. - The health check business received 1,844,454 customers, a significant increase of 89.2% compared to 975,109 customers in the same period last year[26]. - The average spending per customer for health checks increased to RMB 532.6, up 6.4% from RMB 500.5 in the previous year[26]. - The hospital's outpatient visits in March 2023 reached 380 million nationwide, a year-on-year increase of 11.5%[20]. Financial Position - As of June 30, 2023, the company's financial liabilities amounted to RMB 2,988.9 million, a decrease from RMB 3,426.6 million as of December 31, 2022, representing a reduction of approximately 12.8%[61]. - The total book value of assets pledged for the company's borrowings was RMB 182,374,000 as of June 30, 2023, down from RMB 202,739,000 as of December 31, 2022[62]. - The company's total equity and liabilities amounted to RMB 4,259,058 thousand as of June 30, 2023, down from RMB 4,566,858 thousand at the end of 2022, a decrease of about 6.7%[134]. - The company's equity attributable to owners was RMB 1,075,632,000 as of June 30, 2023, compared to RMB 953,918,000 at the end of 2022[125]. - Total liabilities decreased to RMB 3,233,149 thousand as of June 30, 2023, down from RMB 3,662,032 thousand at the end of 2022, representing a reduction of approximately 11.7%[134]. Shareholder Information - As of June 30, 2023, the directors and CEO held a total of 872,550,000 shares, representing approximately 54.87% of the company's issued share capital[80]. - Major shareholders include Tsui Chi with 872,550,000 shares (54.87%) and Renaissance Healthcare Holdings Limited with 268,286,800 shares (16.87%) as of June 30, 2023[117]. - The company has granted stock options totaling 47,710,500 shares under the pre-IPO stock option plan, representing approximately 3.0% of the total issued share capital as of the reporting date[100]. - The stock options will vest over a period of six years, with 70% vesting after six years, which aligns incentives for long-term value creation[101]. Compliance and Governance - The independent auditor conducted a review of the interim financial statements in accordance with Hong Kong Review Standards, confirming no significant issues were found[64]. - The company’s directors confirmed compliance with the standard code during the reporting period, with no known breaches by senior management[67]. - The company has committed to ensuring compliance with public float requirements, indicating a focus on maintaining regulatory standards[108].

Revenue Performance - For the six months ended June 30, 2023, the total revenue reached RMB 1,284,340,000, representing a 59.6% increase compared to RMB 804,538,000 for the same period in 2022[24] - The health check business revenue surged by 101.2% to RMB 982,535,000, up from RMB 488,439,000 in the previous year[24] - The comprehensive hospital business revenue decreased by 3.1% to RMB 312,416,000, down from RMB 322,260,000 in the same period last year[24] - The total revenue from continuing operations for the six months ended June 30, 2023, was RMB 1,284.34 million, an increase of 59.5% compared to RMB 804.54 million for the same period in 2022[88] - The revenue from the health check-up business reached RMB 982.5 million, an increase of 101.2% compared to RMB 488.4 million in the same period of 2022[197] Profitability - The net profit from continuing operations for the period was RMB 126.22 million, a turnaround from a loss of RMB 74.44 million in the same period last year[88] - The company reported a total comprehensive income of RMB 129.91 million for the period, compared to a loss of RMB 168.55 million in the previous year[89] - The group reported a net profit of RMB 126.2 million for the period, compared to a loss of RMB 168.6 million in the previous year[102] - The profit attributable to owners of the company for the six months ended June 30, 2023, was RMB 123.4 million, compared to a loss of RMB 117.9 million for the same period in 2022[105] - Basic and diluted earnings per share from continuing operations were RMB 0.08, compared to a loss of RMB 0.02 for the same period in 2022[101] Expenses and Costs - The sales cost for the continuing operations during the reporting period was RMB 800.3 million, an increase of 24.5% compared to RMB 642.6 million in the same period of 2022[26] - The company reported employee benefit expenses of RMB 496,103,000 for the first half of 2023, an increase of 14.9% from RMB 431,547,000 in the same period of 2022[13] - The cost of sales for the health check business was RMB 569.0 million, up 43.0% from RMB 398.0 million in the same period last year, primarily due to increased variable costs associated with higher business volume[174] - The company incurred administrative expenses of RMB 100,393,000 during the reporting period[137] - The company's administrative expenses for the reporting period were RMB 100.4 million, a slight increase from RMB 97.4 million in the same period of 2022[200] Assets and Liabilities - The company’s total liabilities decreased to RMB 398,925,000 as of June 30, 2023, compared to RMB 481,852,000 as of December 31, 2022, indicating a reduction of 17.2%[10] - The total assets decreased to RMB 4,259.06 million as of June 30, 2023, from RMB 4,566.86 million at the end of 2022[87] - The total liabilities as of June 30, 2023, amounted to RMB 3,233.1 million, a decrease from RMB 3,662.0 million as of December 31, 2022[108] - Current liabilities exceeded current assets by RMB 827.2 million as of June 30, 2023[113] - The group’s total trade receivables decreased from RMB 287,752,000 to RMB 256,360,000 over the six-month period[143] Operational Highlights - The nursing home under Nantong Ruici had an occupancy rate of 100% with 106 residents as of June 30, 2023, compared to 96.2% with 102 residents in the same period of 2022[47] - The number of outpatient services provided was 174,756, representing a year-on-year growth of 6.6%, while inpatient services increased by 22.9% to 14,977[168] - The number of customers served in the health check-up segment rose to 1,844,454, a significant increase of 89.2% from 975,109 in the same period last year[195] - The average spending per customer in the health check-up segment increased by 6.4% to RMB 532.6 from RMB 500.5 in the previous year[195] - The company anticipates continued recovery in hospital treatment volumes in the second half of 2023, driven by the easing of pandemic control measures[192] Strategic Initiatives - The company plans to enhance its medical service capacity with the opening of a new 12-story comprehensive ward building at Nantong Ruici Hospital, increasing bed capacity to 1,500[20] - The company is focusing on expanding its health check services in response to the growing demand driven by an aging population and increasing health awareness[19] - The company has established partnerships with Fudan University and Yangzhou University to enhance its medical talent development and service quality[20] - The group has plans to enhance customer satisfaction through various initiatives and improve medical quality control, focusing on key disciplines such as ultrasound and imaging[48] - The company continues to focus on dual-brand operations and market expansion in key areas such as Shanghai and Jiangsu, while exploring opportunities in other major cities[169]

Financial Performance - For the year ended December 31, 2022, the revenue from continuing operations was RMB 2,375.0 million, a decrease of 0.1% compared to RMB 2,377.2 million for the year ended December 31, 2021[57]. - The gross profit from continuing operations for the year ended December 31, 2022, was RMB 927.2 million, down 4.9% from RMB 975.2 million for the year ended December 31, 2021[57]. - The profit attributable to owners of the company for the year ended December 31, 2022, was RMB 290.8 million, compared to RMB 181.6 million for the year ended December 31, 2021[57]. - The company reported a total revenue of HKD 1.2 billion for the fiscal year ending December 31, 2022, representing a year-on-year increase of 15%[72]. - For the year ended December 31, 2022, the adjusted EBITDA for continuing operations was RMB 819.1 million, a decrease of 2.9% compared to RMB 843.2 million for the year ended December 31, 2021[75]. - Total revenue for the year ended December 31, 2022, was RMB 2,375.0 million, slightly down from RMB 2,377.2 million in 2021[77]. - The net profit attributable to the owners of the company for the year ended December 31, 2022, was RMB 290.8 million, compared to RMB 181.6 million in 2021, representing an increase of 60.4%[77]. - Comprehensive hospital business revenue decreased by 10.5% to RMB 609.6 million in 2022, primarily due to an 11.1% decline in inpatient numbers[125]. - Health check-up business revenue increased by 4.1% to RMB 1,765.4 million in 2022, driven by a 0.5% growth in the number of check-ups and a 3.5% increase in average spending per customer[125]. Operational Highlights - The total number of employees increased to 1,500, with a turnover rate of 10% across various demographics[69]. - The number of inpatient visits at Nantong Ruici Hospital reached 26,141 in 2022, down from 29,395 in 2021, while outpatient visits were 356,610, slightly down from 357,611 in 2021[82]. - In 2022, Nantong Ruici Hospital's revenue reached RMB 631.1 million[82]. - The health check business received a total of 3,258,925 customers, generating revenue of RMB 1,765.39 million, which represents a 4.1% increase compared to 2021[84]. - The company continues to implement a dual-brand strategy with "Ruici Health Check" and "Xingyuan International Health Check," focusing on key markets in Shanghai and Jiangsu while exploring new markets in the Greater Bay Area[84]. - The company launched the second phase of the Xinyuanhui International Health Check-up Center in September 2022, aiming to meet diverse medical service needs[106]. Strategic Initiatives - The company aims to reduce greenhouse gas emissions by 20% by 2025, with specific steps outlined to achieve this target[68]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2025[65]. - The company aims to enhance operational efficiency and meet new consumer demands for health check services in the post-pandemic era[85]. - The management team expresses confidence in the significant development potential of the healthcare industry, driven by a large population base, aging trends, technological innovation, and deepening healthcare reforms[85]. - The company is committed to high-quality development in the healthcare service industry as part of the 14th Five-Year Plan[104]. Governance and Compliance - As of December 31, 2022, the group had no significant legal disputes[11]. - There were no significant transactions or contracts involving directors or their related entities during the year ended December 31, 2022[1]. - The group did not pay any remuneration to directors or the top five highest-paid individuals as bonuses for joining or leaving the group during the year ended December 31, 2022[4]. - The group has adopted a share option scheme as an incentive for directors and eligible employees[4]. - The group confirmed compliance with a non-competition agreement established with its controlling shareholders as of December 31, 2022[8]. - The board of directors consists of seven members, including executive and independent non-executive directors[24]. Environmental and Safety Measures - The total water consumption was reported at 500,000 cubic meters, with a density of 0.5 cubic meters per production unit[67]. - The company has implemented new safety measures, resulting in a 30% reduction in workplace accidents over the past three years[66]. - The total amount of hazardous waste generated was reported at 1,000 tons, with a goal to reduce this by 15% in the next fiscal year[62]. - The company has identified and addressed significant climate-related risks, implementing a comprehensive policy to mitigate these impacts[61]. Financial Position - The total assets as of December 31, 2022, amounted to RMB 4,566.9 million, an increase from RMB 4,536.2 million in 2021[77]. - The total liabilities as of December 31, 2022, were RMB 3,662.0 million, a decrease from RMB 3,948.8 million in 2021[77]. - The company's current liabilities exceeded current assets by RMB 797.5 million as of December 31, 2022, compared to RMB 588.4 million in 2021[155]. - Cash and cash equivalents as of December 31, 2022, were RMB 720.1 million, down from RMB 771.3 million in 2021[156]. - The debt-to-equity ratio improved to 63.6% as of December 31, 2022, compared to 77.1% in 2021, due to a decrease in net financing and an increase in total equity[167]. Board Diversity and Development - The board consists of 4 executive directors (57.1%) and 3 independent non-executive directors (42.9%) as of December 31, 2022[190][191]. - The gender diversity on the board is 4 males (57.1%) and 3 females (42.9%)[193][194]. - The company aims for a minimum gender ratio of 10% for both the board and senior management, with currently 50% of senior management being female[195]. - Approximately 80.7% of the total workforce are female employees[195]. - The company provides ongoing professional development for all directors, ensuring they stay updated on relevant laws and regulations[199].

Financial Performance - For the year ended December 31, 2022, the revenue from continuing operations was RMB 2,375.0 million, a decrease of 0.1% compared to RMB 2,377.2 million for the year ended December 31, 2021[8]. - The adjusted EBITDA for continuing operations was RMB 819.1 million, down 2.9% from RMB 843.2 million in the previous year[5]. - The gross profit for continuing operations was RMB 927.2 million, a decrease of 4.9% from RMB 975.2 million in 2021[8]. - The net profit attributable to the company's owners was RMB 290.8 million, compared to RMB 181.6 million in the previous year[8]. - The operating profit for the year was RMB 431.7 million, down from RMB 516.4 million in the previous year[24]. - The company reported a profit of RMB 267,187 thousand for the year, compared to RMB 126,105 thousand in the previous year, representing an increase of approximately 112%[26]. - Earnings per share (EPS) increased to RMB 0.18 from RMB 0.11, reflecting a growth of 63.64% year-over-year[26]. - The company reported a net profit from continuing operations of RMB 293,702 thousand for the year[42]. - The group reported a net profit attributable to owners of the company from continuing operations of RMB 233,124,000, down from RMB 298,349,000 in 2021[126]. - Net profit for 2022 was RMB 267.2 million, significantly up from RMB 126.1 million in 2021, primarily due to increased revenue from the health check-up segment and gains from the sale of a specialty hospital[151]. Revenue Breakdown - The revenue from outpatient services was RMB 88,122 thousand, down from RMB 90,805 thousand, a decrease of about 3.0%[98]. - The revenue from inpatient services was RMB 230,269 thousand, down from RMB 247,210 thousand, a decrease of approximately 6.9%[98]. - Revenue from health check services reached RMB 1,765,390,000, representing a growth of 4.1% from RMB 1,696,363,000 in 2021[113]. - Health check-up business revenue increased by 4.1% to RMB 1,765.4 million in 2022, driven by a 0.5% growth in the number of check-ups and a 3.5% increase in average spending per person[140]. - Revenue from comprehensive hospital services decreased by 10.4% to RMB 631,112,000 from RMB 704,209,000 in 2021, primarily due to an 11.1% decline in inpatient numbers[113]. Assets and Liabilities - Total assets as of December 31, 2022, amounted to RMB 4,566,858 thousand, a slight increase from RMB 4,536,199 thousand in 2021[28]. - The total liabilities amounted to RMB 3,662,032,000, while total equity was RMB 904,826,000[59]. - The current liabilities exceeded current assets by approximately RMB 797,540,000 as of December 31, 2022[49]. - The company’s total assets were RMB 4,566,858,000, with total liabilities and equity combined at the same amount[59]. - The asset-liability ratio improved to 63.6% as of December 31, 2022, down from 77.1% in 2021, due to a decrease in net financing and an increase in total equity[160]. Cash Flow and Financing - The company’s cash flow for operational needs is primarily supported by cash generated from operating activities and bank borrowings[49]. - The company has confidence in future operating cash flows and the ability to extend bank financing if necessary[49]. - The company plans to meet future cash flow needs through operating cash flow, borrowings from financial institutions, and issuing debt instruments or shareholder contributions[193]. - The company’s interest expenses for the year were RMB 123,052,000[59]. - The net financing cost for the continuing operations in 2022 was RMB 104.9 million, a decrease from RMB 125.1 million in 2021[172]. Operational Metrics - The total outpatient services provided by Nantong Ruici Hospital was 356,610, a slight decrease of 0.3% from 357,611 in 2021[4]. - The number of inpatient services provided decreased by 11.1% to 26,141 from 29,395 in the previous year[4]. - The company operates 74 health check centers nationwide, with 60 already in operation, covering 29 cities, primarily in first-tier, new first-tier, and second-tier cities[107]. - The group received a total of 3,258,924 customers for health check services in the reporting period, a slight increase of 0.5% compared to 3,243,761 in 2021[109]. - As of December 31, 2022, the nursing home had 101 residents with an occupancy rate of 94.2%, down from 95.3% in 2021, reflecting a decrease of 1.1 percentage points[107]. Strategic Initiatives - The company plans to continue its dual-brand strategy with "Ruici Health Check" and "Xingyuan International Health Check" to meet new consumer demands post-pandemic[2]. - The company aims to deepen its market presence in Shanghai and Jiangsu while actively developing the Greater Bay Area and Zhejiang markets[2]. - The company is focusing on expanding its market presence in the Greater Bay Area and other core cities while maintaining its dual-brand strategy in health check services[107]. - The company has signed cooperation agreements with six prestigious hospitals in Shanghai to develop specialized clinical medical centers, enhancing its service capabilities[106]. - The group is focusing on enhancing service quality and optimizing service processes in the health check segment, with significant improvements noted[135]. Cost and Expenses - Employee benefits expenses increased to RMB 901,209 thousand in 2022 from RMB 809,984 thousand in 2021, representing an increase of approximately 11.4%[99]. - The total operating expenses for the year ended December 31, 2022, amounted to RMB 1,953,633 thousand, up from RMB 1,875,127 thousand in 2021, reflecting a growth of about 4.2%[99]. - Sales costs rose by 3.3% from RMB 1,402.0 million in 2021 to RMB 1,447.8 million in 2022[142]. - The sales cost for the health check business in 2022 was RMB 977.0 million, an increase of 8.9% compared to RMB 897.2 million in 2021, primarily due to the expansion of the revenue scale[168]. Dividends and Shareholder Returns - The company did not declare or pay any dividends for the year ended December 31, 2022, consistent with 2021[102].

Financial Performance - RICI Healthcare reported a revenue of HKD 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[1] - The company achieved a net profit of HKD 300 million, which is a 20% increase compared to the same period last year[1] - The company has set a revenue guidance of HKD 2.5 billion for the full year 2022, reflecting a growth target of 10%[1] - The company's revenue decreased by 12.4% from RMB 999.5 million in the six months ended June 30, 2021, to RMB 875.6 million in the current reporting period, primarily due to the impact of the pandemic on operations[25] - Total revenue for the six months ended June 30, 2022, was RMB 875,633 thousand, a decrease of 12.4% compared to RMB 999,533 thousand for the same period in 2021[185] - The health check business, which is the largest revenue segment, reported a revenue decline of 20.0%, from RMB 610.8 million in 2021 to RMB 488.4 million in 2022[24] - The company recorded a decrease in revenue from health check services to RMB 487,882 thousand, down 20.1% from RMB 610,542 thousand in 2021[185] Operational Highlights - User data indicated a growth in patient visits by 25%, reaching a total of 500,000 visits in the first half of 2022[1] - The company reported a 30% increase in its outpatient services revenue, driven by higher demand for specialized treatments[1] - The company is focusing on enhancing service quality and medical talent training amid ongoing market challenges due to the pandemic[15] - The company plans to expand its market presence by opening 10 new healthcare facilities in the next 12 months[1] - RICI Healthcare is investing HKD 100 million in new technology for telemedicine services to enhance patient care[1] - The company is exploring potential acquisitions to strengthen its service offerings in the healthcare sector[1] Staffing and Facilities - As of June 30, 2022, Nantong Ruici Hospital employed 1,096 staff, an increase from 991 staff as of June 30, 2021, including 328 doctors, up from 303[15] - The hospital's new maternity building was completed in August 2022, while the new comprehensive ward building is still under construction and expected to be operational by the end of the year[15] - The hospital established a strategic cooperation agreement with Fudan University to create a first-class regional medical center, enhancing its service capabilities[13] Financial Position - As of June 30, 2022, the company's current liabilities exceeded current assets by RMB 847.7 million, an increase from RMB 588.4 million as of December 31, 2021, primarily due to a decrease in cash used for the expansion of Nantong Ruici Hospital and the purchase of medical equipment[43] - The company's cash and cash equivalents amounted to RMB 560.9 million as of June 30, 2022, down from RMB 771.3 million as of December 31, 2021, with available bank financing decreasing to RMB 138.2 million from RMB 281.2 million[44] - The company's debt totaled RMB 1,127.9 million as of June 30, 2022, a decrease from RMB 1,248.9 million as of December 31, 2021[47] - The debt-to-equity ratio increased to 82.9% as of June 30, 2022, from 77.1% as of December 31, 2021, primarily due to a decrease in cash and equity during the reporting period[50] Loss and Expenses - The net loss for the period was RMB 168.6 million, compared to a net loss of RMB 30.1 million in the same period of 2021, primarily due to a 12.4% decrease in revenue[38] - Adjusted EBITDA for the period was RMB 108.7 million, a decline of 60.7% from RMB 276.6 million in the same period of 2021[40] - The gross profit decreased to RMB 132.3 million, with a gross margin of 15.1%, down 12.2 percentage points from 27.3% in the same period of 2021[29] - Employee benefit expenses rose to RMB 488,103 thousand, an increase of 21.7% from RMB 401,163 thousand in 2021[187] Shareholder Information - As of June 30, 2022, Dr. Mei and Dr. Fang each held 872,550,000 shares, representing approximately 54.87% of the company's issued share capital[68] - The company confirmed compliance with the corporate governance code, except for deviations regarding insurance for directors and the separation of roles between the chairman and CEO[62][63] - The company has a pre-IPO share option plan that allows for the issuance of up to 47,710,500 shares, which is approximately 3.0% of the company's issued share capital[78] Legal and Dispute Matters - As of June 30, 2022, the group is involved in four unresolved medical disputes related to Nantong Ruici Hospital[200] - The health check center is also involved in several unresolved disputes[200] - The financial risk associated with these ongoing disputes is considered not significant by the group[200] - No additional provisions have been made regarding these disputes[200]

Financial Performance - The company reported a significant increase in revenue for the fiscal year ending December 31, 2021, with total revenue reaching HKD 1.2 billion, representing a year-over-year growth of 15%[3]. - For the fiscal year ended December 31, 2021, the revenue was RMB 2,506.5 million, an increase of 30.2% compared to RMB 1,925.2 million for the fiscal year ended December 31, 2020[14]. - The gross profit for the fiscal year ended December 31, 2021, was RMB 899.1 million, representing a growth of 54.8% from RMB 580.7 million for the fiscal year ended December 31, 2020[14]. - The profit attributable to owners of the company for the fiscal year ended December 31, 2021, was RMB 181.6 million, a significant turnaround from a loss of RMB 7.9 million for the fiscal year ended December 31, 2020[14]. - The adjusted EBITDA for the fiscal year ended December 31, 2021, was RMB 787.1 million, reflecting a growth of 68.1% from RMB 468.2 million for the fiscal year ended December 31, 2020[14]. - The company reported a net profit margin of 12% for the fiscal year, reflecting improved operational efficiencies and cost management strategies[3]. - The company recorded a profit of RMB 126.1 million for the fiscal year ended December 31, 2021, compared to a loss of RMB 92.5 million for the fiscal year ended December 31, 2020[15]. Market Expansion and Strategy - The company has set a future outlook with a revenue growth target of 10-15% for the next fiscal year, driven by expansion into new markets and enhanced service offerings[3]. - The company plans to expand its market presence by opening three new clinics in major cities, aiming for a 25% increase in service capacity[3]. - The company is expanding its market presence in Southeast Asia, aiming for a 10% market share by the end of 2024[28]. - A strategic acquisition of a local healthcare provider is in progress, which is projected to enhance the company's service portfolio and increase market share by 5%[3]. - A strategic acquisition of a local competitor is anticipated to enhance service offerings and increase market penetration[30]. User Engagement and Services - User data showed a 20% increase in patient visits across all facilities, totaling 1.5 million visits in 2021 compared to 1.25 million in 2020[3]. - New product development initiatives include the launch of a telemedicine platform, expected to increase patient engagement by 30%[3]. - The company is implementing a dual-brand strategy with "Ruici Health Check" and "Xingyuan International Health Check Center" to target mid-to-high-end markets[20]. - The health check business experienced a recovery growth in 2021, driven by increased health awareness among the public due to recurring domestic pandemic situations[20]. Research and Development - The company has invested HKD 100 million in research and development for advanced medical technologies, aiming to improve operational efficiency by 20%[3]. - The company is increasing its investment in artificial intelligence and 5G technology to adapt to current data demands in medical equipment[111]. - The company is focusing on enhancing its health data mining capabilities to provide proactive services such as health warnings and to promote service upgrades through collaboration with biotechnology[110]. Sustainability and Environmental Initiatives - The management team emphasized a commitment to sustainability, with plans to reduce operational carbon footprint by 15% over the next three years[3]. - The company emphasizes the importance of environmental protection and has implemented measures to reduce resource consumption and pollution emissions[130]. - In 2021, the company reported full compliance with local environmental regulations, achieving comprehensive control over waste emissions[131]. - The company has set specific goals for reducing air emissions and solid waste, focusing on minimizing its operational impact on the environment[130]. Governance and Compliance - The board of directors has approved a dividend payout of HKD 0.05 per share, representing a 10% increase from the previous year[3]. - The company has established a comprehensive risk management and internal control framework to actively manage risks associated with business expansion and operational uncertainties[109]. - The company has implemented a series of anti-corruption measures to enhance business ethics and compliance[187]. - The company has established arrangements for employees to report concerns regarding financial reporting and internal controls confidentially[106]. Employee Management and Training - The group employs a total of 7,706 employees, with 5,916 in the health check division, 1,097 in the general hospital division, and 506 in the specialty hospital division, maintaining a gender ratio of approximately 1:4[159]. - The employee turnover rate for 2021 is reported at 24.47%[161]. - The company provided RMB 1,500 worth of free health check opportunities annually for employees and their families, enhancing employee recognition and belonging[182]. - The company emphasizes performance evaluation, adhering to principles of performance priority and fair distribution, with 95% of training participants being non-management staff[175]. Community Engagement - In 2021, the company organized 83 community service events, covering 5,200 participants, including 35 free medical consultations[185]. - The company actively participated in COVID-19 response efforts, with over 60 medical staff deployed for community testing in Guangdong in May 2021[183]. - A total of 160 medical staff participated in community prevention efforts during the resurgence of COVID-19 in July 2021, providing testing for tens of thousands of residents[184].